XRESEARCH AND DEVELOPMENT
XNTC TECHNOLOGIES
XCORPORATE PROFILE
XCONTACT US

NEW! NTC VECTORSX|XNEW! HyperTAQ™ X|XDNA VACCINESX|XPROTEINSX|XPLASMIDSX|XDNA FERMENTATION PROCESSX|XPROCESS DEVELOPMENT

Research and Development
Scientific Publications and Books

TechnologiesX|XPatentsX|XPublicationsX|XPress ReleasesX|XPartnering Opportunities

Scientific Publications | Books

Plasmid DNA production combining antibiotic-free selection, inducible high yield fermentation, and novel autolytic purification, Carnes, AE, Hodgson, CP, Luke, JM, Vincent, JM, Williams, JA, Biotechnol. Bioeng. (2009)

Strain engineering by genome mass transfer: efficient chromosomal trait transfer method utilizing donor genomic DNA and recipient recombineering hosts, Williams, JA, Luke, J, Hodgson, CP, Mol. Biotechnol. (2009) 43:41-50-9177-5, (PDF)

Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Luke J, Carnes AE, Hodgson CP, Williams JA. Vaccine (2009)

NTC eRNA DNA vaccines. coexpressed RIG-I agonist enhances antigen-specific immune response to Influenza DNA Vaccine. James Williams Ph.D., Jeremy Luke, B.A., and Clague Hodgson Ph.D.. (2009) (Poster)

Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes. James A Williams *, Jeremy Luke, Sarah Langtry, Sheryl Anderson, Clague P Hodgson, Aaron E Carnes, Nature Technology Corporation, Lincoln, NE, USA. Biotechnol. Bioeng. (2009) 103:1129-1143

Low metabolic burden plasmid production, Carnes AE, Williams JA, Gen Eng. Biotech News, (2009) 29:56-57

Plasmid DNA vaccine vector design; impact on efficacy, safety and upstream production. Williams, J.A., Carnes, A.E., and Hodgson, C.P. (2009). Biotechnology Advances. (2009) 27:35370

Plasmid DNA for vaccine manufacture: high-yield production and rapid analysis,
(2007) Downstream 41:8-11. (PDF)

Rapid deployment plasmid production process combining inducible high yield fed-batch fermentation process with novel autolytic plasmid DNA purification. Luke, J., Langtry, S., Hodgson, C., (2007) Mol. Ther. 15:S187-188. BioProcess Intl 3-9-Carnes.pdf

Plasmid DNA manufacturing technology review. Carnes, A., Williams, J., (2007) Current Patents on Biotechnol. 1(2):151-166.C

Fermentation design for the manufacture of therapeutic plasmid DNA. Carnes, AE (2006) October, 2006 "Mounted on the Internet with permission from BioProcess International”.

Inducible Escherichia coli fermentation for increased plasmid DNA production. Carnes AE, Hodgson CP, Willims, JA. (2006) Biotechnol. Appl. Biochem. 45:155-166. "Mounted on the internet with permissiion from Portland Press.

pDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids. James A Williams, Jeremy Luke, Lance Johnson, Clague Hodgson, (2006) Vaccine 24:4671-4676;

Sperm endogenous reverse transcriptase as mediator of new genetic information. Sciamanna I, Bargeri L, Martire A, Pittoggi C, Beralda R, Giordana R, Magnano AR, Hodgson C, Spadafora C. (2003) Biochem. Biophys. Res. Commun. 312: 1039-.

Gene self-assembly technology (GENSA) Hodgson, C.P., (2002) , in: G. Subramanian, Ed., Gene Therapy: Clinical, Scale-Up and Production, Elsevier Academic Publishers.

Sustained tissue-specific transgene expression from a VL30 retrotransposon-derived vector in vivo. Grunkemeyer, J.A., Hodgson, C.P., Cosgrove, D. (2001) Gene Ther. Mol. Biol. 6:91-99 (PDF).

Modular retro-vectors for transgenic and therapeutic use. Solaiman, F., Zink, M.A., Xu, G., Grunkemeyer, J., Cosgrove, D., Saenz., J., and Hodgson, C.P. (2000) Mol. Repro. & Dev. 56: 309-315

DNA-dose and sequence dependency in sperm-mediated gene transfer. Sciamanna, I., Piccoli, S., Barberi, Zaccagnini, G., Magnano, A.R., Giordano, R., Campedelli, P., Hodgson, C.P., Lorenzini, R., and Spadafora, C. (2000) Mol. Repro. & Dev. 56:301-305.

Fusogenic effects of murine retroviruses and cationic enhancers of transduction. Xu, G., Hodgson, C.P. (2000) Cancer Gene Therapy 7:53-58.

Progress toward synthetic retro-vectoring systems for gene therapy. Hodgson, C.P. Xu. G., Solaiman, F., Zink, M.A. (1997) J. Mol. Med. 75:249-258.

Chimeric viral packaging signal without gag gene sequences. Hodgson, C.P., Zink, M.A., Xu, G.-P. (1999) World Patent Publication WO 99/25862.

Role of far upstream sequences regulating the rat Ha-ras gene expression. Chakraborty, A.K., Hodgson, C.P., (1998) Biochem. Biophys. Res. Commun. 252:716-722.

Progress toward synthetic retro-vectoring systems for gene therapy. Hodgson, C.P. Xu. G., Solaiman, F., Zink, M.A. (1997) J. Mol. Med. 75:249-258.

Virosomes: Cationic liposomes enhance retroviral transduction. Hodgson, C.P. and Solaiman, F. (1996). Nature Biotechnol. 14:339-342.

Biosynthetic Virus Vectors for Gene Therapy. Hodgson, C.P. (1996) World Intellectual Property Organization (WIPO) Patent Publication WO 96/26745, 41p.

The vector void in gene therapy. Hodgson, C.P. (1995). Bio/Technology 11:222-225.

Retro-vectors for human gene therapy. 6 chapters. Hodgson, C.P. ed., (1996, 2001) (Chapman and Hall, New York; Springer-Verlag, Berlin, Heidelberg; Prairie Publishing, Omaha).
i